Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
about
Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsLinkers Having a Crucial Role in Antibody-Drug ConjugatesThe clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemiaAntibody-drug conjugates as novel anti-cancer chemotherapeuticsAntibody Drug Conjugates: Preclinical ConsiderationsDevelopment and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic CancerNew Therapeutic Strategies in Acute Lymphocytic Leukemia.Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.Antibodies to watch in 2010A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv.Inotuzumab ozogamicin as novel therapy in lymphomas.Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide.Novel agents for the treatment of childhood acute leukemia.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphomaTarget Therapy in Hematological Malignances: New Monoclonal Antibodies.Linked-in: design and efficacy of antibody drug conjugates in oncologyCombination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.Antibody-based therapy of leukaemia.Mantle cell lymphoma: state-of-the-art management and future perspective.Advances in the treatment of hematologic malignancies using immunoconjugatesChallenges in developing bioanalytical assays for characterization of antibody-drug conjugates.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.The future role of monoclonal antibody therapy in childhood acute leukaemias.Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.Novel targeted therapies in acute lymphoblastic leukemia.Trends in cancer-targeted antibody-drug conjugates.Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies.Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug ConjugatesCMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
P2860
Q24624489-605F5B25-F0EC-46DD-9FB2-6B65158169FFQ26752763-7FEC2249-B976-4278-98EC-4B814C5A3FC7Q26783425-FD3E5E62-F124-4689-A697-5E15A006E666Q26800175-829DB5BE-D14C-4991-AB2F-8AEC93A4B571Q27022321-658B06B9-E54A-4EEE-B663-8A8BC73BDE6AQ28552050-832299C5-D3DB-44DE-BDF1-CB8C91C751A6Q30252776-00579CD5-9313-43A6-951F-2A9B913D1EA4Q33311571-FD884F05-119D-4C62-89C2-47B84417BE29Q33399704-83245C47-ACC8-41BF-8782-427CEA182EAAQ33405150-9E178F82-35A5-49B6-A01B-56576EDC0546Q33431680-30CF1197-3FD9-4492-8051-053FE2A92533Q33434352-372E8FC4-6F2E-417D-A614-D67BC43B5000Q33688243-F718AAD4-F3DA-4EB5-BCE7-FB1E9160BEC3Q33758660-B30554AC-7A74-454F-8A0A-855B2EDDD256Q33767470-4C651E47-BA76-4DFE-B394-4F4AEB644461Q34620271-B8AB3EC8-A0E3-4F2F-AEFE-F30CFE5EBB2FQ34818576-D4773E37-6AF3-4F40-B63B-8681CC2D5A36Q35192790-5A97B53D-2323-4E6D-9C32-E6C7FD4CD385Q35980938-4361CCC7-4DE3-4019-AF87-805A5A4FC309Q35992515-827C163C-ED0A-4B67-BA58-BAB04E748705Q36476080-9CF2237C-E1E8-41CA-9D78-D6E22BA0B767Q36979140-214D19F9-9499-4FE0-BDF9-55E01AC3F8DFQ37029370-A2D723D4-DF53-46CB-BF45-8771F4AE36AEQ37299843-CAD517BB-F1FC-4E15-81EB-2BA062A5EA0DQ37605247-9CE86DFE-C2A3-41EB-BA3C-123C19DC0428Q37622873-3C0C7B4F-BE35-4C6C-AAD6-067E8A1A6E97Q37697843-B88F3EC3-10F5-45B4-A95B-FC485C02DA04Q37854644-9730BF9D-8B5A-4D98-A30C-3FEAC63442E7Q37913356-79CA0980-82EB-4F15-83A0-A2B4826DF135Q38002447-D7BD87CE-8018-4E3E-99BC-AC8765F51088Q38033600-F8A7B526-5A4E-44AC-AB80-D3EA6E1D1358Q38087390-67E98805-DDCF-430B-81CF-D50A5BF8EAE5Q38120551-A7858CE5-E52F-4F5D-9731-3D0A091D3B43Q38162127-57FBFEC9-EED1-4184-93FE-0570B46AF860Q38188591-1BDACBA1-E0B2-4EC1-A378-E5F447537BA8Q38262066-17FA7E99-84EB-47D4-AE87-629625070669Q38355000-7E4F47EC-2406-48C1-A1A2-D8FBF5F03569Q38379829-C8516622-7827-44E1-A183-9ACF0FD9B1E4Q38489049-77A899C8-2CE1-43E8-9E29-D175A46DA085Q38550992-AA889D2B-785D-4F7D-A612-5D1654CEE0F9
P2860
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.
@ast
Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.
@en
Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.
@nl
type
label
Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.
@ast
Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.
@en
Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.
@nl
prefLabel
Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.
@ast
Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.
@en
Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.
@nl
P2093
P1433
P1476
Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.
@en
P2093
Andrew G Popplewell
Arthur Kunz
Boris Gorovits
Chandrasekhar Udata
Douglas C Armellino
Erwin R Boghaert
John F DiJoseph
Justin K Moran
Kiran Khandke
Latha Sridharan
P304
P356
10.1182/BLOOD-2003-07-2466
P407
P577
2003-11-13T00:00:00Z